JOP20210338A1 - نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد - Google Patents
نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميدInfo
- Publication number
- JOP20210338A1 JOP20210338A1 JOP/2021/0338A JOP20210338A JOP20210338A1 JO P20210338 A1 JOP20210338 A1 JO P20210338A1 JO P20210338 A JOP20210338 A JO P20210338A JO P20210338 A1 JOP20210338 A1 JO P20210338A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- thiazol
- benzamide
- pyrimidin
- analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يغطي الاختراع الحالي مركبات من مثبط P2X3 ذات الصيغة العامة (I): (I)، حيث يكون R1 وR2 كما تم تعريفهما هنا، ويغطي طرق لتحضير المركبات المذكورة، والمركبات الوسطية المفيدة لتحضير المركبات المذكورة، وتراكيب صيدلانية وتوليفات تشتمل على المركبات المذكورة، واستخدام المركبات المذكورة لتصنيع التراكيب الصيدلانية للمعالجة أو الوقاية من الأمراض، بالتحديد اضطرابات عصبية المنشأ، كعامل وحيد أو في توليفة مع مقومات نشطة أخرى.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19182797.1A EP3757103A1 (en) | 2019-06-27 | 2019-06-27 | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
PCT/EP2020/067828 WO2020260463A1 (en) | 2019-06-27 | 2020-06-25 | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210338A1 true JOP20210338A1 (ar) | 2023-01-30 |
Family
ID=67105828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0338A JOP20210338A1 (ar) | 2019-06-27 | 2020-06-25 | نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230013419A1 (ar) |
EP (2) | EP3757103A1 (ar) |
JP (1) | JP2022538270A (ar) |
KR (1) | KR20220027860A (ar) |
CN (1) | CN114026086A (ar) |
AU (1) | AU2020303269A1 (ar) |
BR (1) | BR112021024325A2 (ar) |
CA (1) | CA3145204A1 (ar) |
CL (1) | CL2021003455A1 (ar) |
CO (1) | CO2021017435A2 (ar) |
CR (1) | CR20210686A (ar) |
EC (1) | ECSP21088111A (ar) |
IL (1) | IL289161A (ar) |
JO (1) | JOP20210338A1 (ar) |
MA (1) | MA56383A (ar) |
MX (1) | MX2021015853A (ar) |
PE (1) | PE20220219A1 (ar) |
WO (1) | WO2020260463A1 (ar) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY192690A (en) | 2014-12-09 | 2022-09-01 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides |
AU2021282039A1 (en) * | 2020-05-25 | 2022-12-01 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Arylformamide compound and preparation method and medical use thereof |
CN115884970A (zh) * | 2020-09-24 | 2023-03-31 | 中国医药研究开发中心有限公司 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
JP2023543066A (ja) * | 2020-09-30 | 2023-10-12 | ヒューマンウェル ヘルスケア (グループ) カンパニー リミテッド | ベンザミド類化合物及びその使用 |
TW202404965A (zh) * | 2022-03-29 | 2024-02-01 | 大陸商人福醫藥集團股份公司 | P2x3抑制劑化合物及其鹽、多晶型和用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008055840A1 (en) * | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Thiazole and oxazole-substituted arylamides |
US8501933B2 (en) * | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
SG172190A1 (en) * | 2008-12-16 | 2011-07-28 | Hoffmann La Roche | Thiadiazole-substituted arylamides |
WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
MY192690A (en) | 2014-12-09 | 2022-09-01 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides |
AU2019269047A1 (en) * | 2018-05-15 | 2020-11-26 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
TWI780329B (zh) * | 2018-05-15 | 2022-10-11 | 德商拜耳廠股份有限公司 | 經1,3-噻唑-2-基取代之苯甲醯胺用於治療與神經纖維敏化作用相關疾病之用途 |
-
2019
- 2019-06-27 EP EP19182797.1A patent/EP3757103A1/en not_active Withdrawn
-
2020
- 2020-06-25 US US17/620,410 patent/US20230013419A1/en active Pending
- 2020-06-25 CN CN202080046297.9A patent/CN114026086A/zh active Pending
- 2020-06-25 PE PE2021002216A patent/PE20220219A1/es unknown
- 2020-06-25 WO PCT/EP2020/067828 patent/WO2020260463A1/en active Application Filing
- 2020-06-25 CA CA3145204A patent/CA3145204A1/en active Pending
- 2020-06-25 JP JP2021577052A patent/JP2022538270A/ja active Pending
- 2020-06-25 AU AU2020303269A patent/AU2020303269A1/en not_active Abandoned
- 2020-06-25 CR CR20210686A patent/CR20210686A/es unknown
- 2020-06-25 JO JOP/2021/0338A patent/JOP20210338A1/ar unknown
- 2020-06-25 MX MX2021015853A patent/MX2021015853A/es unknown
- 2020-06-25 KR KR1020217042065A patent/KR20220027860A/ko not_active Application Discontinuation
- 2020-06-25 MA MA056383A patent/MA56383A/fr unknown
- 2020-06-25 EP EP20734210.6A patent/EP3990453A1/en active Pending
- 2020-06-25 BR BR112021024325A patent/BR112021024325A2/pt unknown
-
2021
- 2021-12-03 EC ECSENADI202188111A patent/ECSP21088111A/es unknown
- 2021-12-20 CO CONC2021/0017435A patent/CO2021017435A2/es unknown
- 2021-12-20 IL IL289161A patent/IL289161A/en unknown
- 2021-12-23 CL CL2021003455A patent/CL2021003455A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020303269A1 (en) | 2022-02-03 |
IL289161A (en) | 2022-02-01 |
MX2021015853A (es) | 2022-02-03 |
MA56383A (fr) | 2022-05-04 |
EP3757103A1 (en) | 2020-12-30 |
CR20210686A (es) | 2022-02-09 |
CA3145204A1 (en) | 2020-12-30 |
US20230013419A1 (en) | 2023-01-19 |
JP2022538270A (ja) | 2022-09-01 |
EP3990453A1 (en) | 2022-05-04 |
CO2021017435A2 (es) | 2022-01-17 |
KR20220027860A (ko) | 2022-03-08 |
WO2020260463A1 (en) | 2020-12-30 |
CL2021003455A1 (es) | 2022-08-05 |
PE20220219A1 (es) | 2022-02-02 |
BR112021024325A2 (pt) | 2022-01-11 |
ECSP21088111A (es) | 2022-01-31 |
CN114026086A (zh) | 2022-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210338A1 (ar) | نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد | |
PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
PH12017501079A1 (en) | 1,3-thiazol-2-yl substituted benzamides | |
JOP20220131A1 (ar) | مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة | |
NZ734516A (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n’-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
JO3447B1 (ar) | 2-(مورفولين-4-يل)-7،1-نفثيريدينات | |
MX2023009388A (es) | Metodos para tratar alteraciones del comportamiento. | |
MX2022013388A (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activacion inmune. | |
WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
BR112018073951A2 (pt) | forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
BR112017010439A2 (pt) | composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto | |
PH12020500134A1 (en) | Dihydrooxadiazinones | |
WO2020126968A3 (en) | Urea derivatives for use against proliferative diseases | |
PH12020550494A1 (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors | |
MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
EA201991490A1 (ru) | Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1 | |
BR112021019779A2 (pt) | Novo composto e composição para prevenção ou tratamento de doenças respiratórias compreendendo os mesmos como ingrediente ativo | |
MX2022003830A (es) | Compuesto de n-(1h-imidazol-2-il)benzamida y composicion farmaceutica que comprende el mismo como ingrediente activo. | |
EA202090241A1 (ru) | Новые гетероциклические соединения как ингибиторы cdk8/19 | |
AR103645A1 (es) | Uso de un depurador de formaldehído en una composición farmacéutica | |
PL431613A1 (pl) | Związek do zastosowania jako lek, inhibitor kinazy PERK oraz jego zastosowanie do zapobiegania i leczenia chorób neurodegeneracyjnych zależnych od stresu retikulum endoplazmatycznego | |
EA201991016A1 (ru) | 2,4,5-трехзамещенные 1,2,4-триазолоны, применяемые в качестве ингибиторов дгодг |